Literature DB >> 7525328

Rapid exit from G0/G1 phases of cell cycle in response to stem cell factor confers on umbilical cord blood CD34+ cells an enhanced ex vivo expansion potential.

C M Traycoff1, M R Abboud, J Laver, D W Clapp, E F Srour.   

Abstract

Currently, the most commonly used grafts of progenitor and stem cells for patients undergoing bone marrow transplantation (BMT) are derived from large collections of autologous or allogeneic adult human bone marrow (BM). The feasibility of using human umbilical cord blood (HUCB), normal peripheral blood (PB), and smaller collections of BM as sources of hematopoietic stem cell grafts for adult patients remains questionable. We investigated the ex vivo proliferative potential of HUCB CD34+ cells as a means of expanding HUCB grafts, thereby making them more acceptable for clinical transplantation. HUCB-derived CD34+HLA-DR+ cells, maintained for 5 days in suspension cultures supplemented with 10% HUCB plasma and a combination of stem cell factor (SCF) and interleukin-3 (IL-3), displayed a 10-fold increase in the total number of CD34+ cells. In contrast, only a four-fold increase was observed in identical cultures initiated with BM-derived CD34+HLA-DR+ cells. Whereas BM CD34+ cells failed to proliferate in response to SCF alone, HUCB CD34+ cells expanded 5.6-fold by day 5, thus demonstrating an enhanced response to SCF. When the effects of SCF on the exit of HUCB cells from G0/G1 phases of cell cycle were investigated, we found that although HUCB CD34+HLA-DR+ cells were more quiescent than BM CD34+HLA-DR+ and BM CD34+HLA-DR- cells (97.5% of HUCB CD34+HLA-DR+ in G0/G1 vs. 88.6% of BM CD34+HLA-DR+ and 92.0% of BM CD34+HLA-DR- [p < 0.005]), HUCB CD34+HLA-DR+ cells exited from dormancy more rapidly than BM cells, such that by 36 to 48 hours following exposure to SCF, only 55% remained in G0/G1. Furthermore, an 8.4-fold increase in the number of HUCB CD34+ cells still residing in G0/G1 was observed on day 5 in cultures supplemented with SCF and IL-3, suggesting the generation of large numbers of primitive hematopoietic progenitor cells (HPC) in vitro. When the contribution of HUCB plasma to the exist of HUCB CD34+HLA-DR+ cells from G0/G1 phases of cell cycle was investigated, it was found that in serum-free media supplemented with only SCF or IL-3, HUCB cells did not exist G0/G1 as rapidly as when HUCB plasma or SCF plus IL-3 was present. In contrast, when HUCB plasma was added to any cytokine combination, it did not enhance the exist of BM CD34+HLA-DR+ cells from G0/G1 phases of cell cycle.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7525328

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  10 in total

1.  Cell cycle status of CD34+ cells in human fetal bone marrow.

Authors:  J M Koenig; B Luttge; N A Benson; R D Christensen
Journal:  Early Hum Dev       Date:  2001-12       Impact factor: 2.079

2.  Trophic factor induction of human umbilical cord blood cells in vitro and in vivo.

Authors:  Ning Chen; Siddharth Kamath; Jennifer Newcomb; Jennifer Hudson; Svitlana Garbuzova-Davis; Paula Bickford; Cyndy Davis-Sanberg; Paul Sanberg; Tanja Zigova; Alison Willing
Journal:  J Neural Eng       Date:  2007-04-04       Impact factor: 5.379

3.  What is the future for cord blood stem cells?

Authors:  E A de Wynter
Journal:  Cytotechnology       Date:  2003-03       Impact factor: 2.058

4.  Differences amid bone marrow and cord blood hematopoietic stem/progenitor cell division kinetics.

Authors:  Cláudia Lobato da Silva; Raquel Gonçalves; Christopher D Porada; João L Ascensão; Esmail D Zanjani; Joaquim M S Cabral; Graça Almeida-Porada
Journal:  J Cell Physiol       Date:  2009-07       Impact factor: 6.384

5.  HIV, but not murine leukemia virus, vectors mediate high efficiency gene transfer into freshly isolated G0/G1 human hematopoietic stem cells.

Authors:  N Uchida; R E Sutton; A M Friera; D He; M J Reitsma; W C Chang; G Veres; R Scollay; I L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-29       Impact factor: 11.205

Review 6.  Therapeutic potentials of human embryonic stem cells in Parkinson's disease.

Authors:  Mary B Newman; Roy A E Bakay
Journal:  Neurotherapeutics       Date:  2008-04       Impact factor: 7.620

7.  Selective Expansion of CD34+ Cells from Mouse Bone Marrow Cultured on LH/P MP-Coated Plates with Adequate Cytokines.

Authors:  Satoko Kishimoto; Masayuki Ishihara; Yasuhiro Kanatani; Masaki Nambu; Megumi Takikawa; Yuki Sumi; Shingo Nakamura; Yasutaka Mori; Hidemi Hattori; Yoshihiro Tanaka; Toshinori Sato
Journal:  J Tissue Eng       Date:  2011-10-30       Impact factor: 7.813

8.  EDAG promotes the expansion and survival of human CD34+ cells.

Authors:  Ke Zhao; Wei-Wei Zheng; Xiao-Ming Dong; Rong-Hua Yin; Rui Gao; Xiu Li; Jin-Fang Liu; Yi-Qun Zhan; Miao Yu; Hui Chen; Chang-Hui Ge; Hong-Mei Ning; Xiao-Ming Yang; Chang-Yan Li
Journal:  PLoS One       Date:  2018-01-11       Impact factor: 3.240

9.  Wharton's jelly mesenchymal stem cell-based or umbilical vein endothelial cell-based serum-free coculture with cytokines supports the ex vivo expansion/maintenance of cord blood hematopoietic stem/progenitor cells.

Authors:  Qiuyang Li; Dewan Zhao; Qiang Chen; Maowen Luo; Jingcao Huang; Cao Yang; Fangfang Wang; Wenxian Li; Ting Liu
Journal:  Stem Cell Res Ther       Date:  2019-12-05       Impact factor: 6.832

10.  Evaluation of hematopoietic stem cell expansion in the presence of garcinol.

Authors:  Azam Habibi; Masoud Soleimani; Amir Atashi; Mahshid AkhavanRahnama; Azadeh Anbarlou; Mansoureh Ajami; Monireh Ajami
Journal:  Avicenna J Phytomed       Date:  2018 Jul-Aug
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.